of bites are reported each year, but fewer than half a dozen are fatal. 2, 3 Snakebite mortality has decreased through the years and in certain regions of the world, in part because of the development of safe and effective antivenoms. 4, 5 Antivenoms bind and neutralize venom toxins, and facilitate redistribution away from target tissues and elimination from the body. 6, 7 Antivenom production involves collecting venom from a medically signifi cant organism and inoculating a suitable domestic animal. 8 Sublethal amounts generate immunity, and antibodies are obtained from the plasma of the immunized animal. 9 Adverse drug reactions to early, unrefi ned antiserums were frequent, often severe and sometimes fatal. 5, 10, 11 Physicians were, therefore, hesitant to use antivenom, and fear of dangerous side effects led to delays in administration and to insuffi cient dosing. Most modern antivenoms undergo further modifi cation, 9,12,13 including plasma fractionation, protein precipitation, ion-exchange or affi nity chromatography, ultra-and nanofi ltration, addition of preservative, lyophilization, and the regulation via Good Manufacturing Practices for quality control and minimization of microbial contamination. Further, many manufacturers enzymatically reduce the crude Immunoglobulin G (IgG) molecule to yield antigen-binding fragments. The Y-shaped IgG is cleaved with pepsin to yield a V-shaped F(ab ' ) 2 or with papain to generate two Fab fragments. The Fc portion (the stem of the Y), suspected for causing most of the adverse reactions, is removed along with other non-neutralizing components. Immune reactions are now markedly less problematic than those with earlier and less ameliorated preparations. 4, 5 Importance However, another kind of clinical problem emerged as Fab antivenom gained widespread use in the US, 7 where it has been the only commercially available antidote for pit viper (Crotalinae) envenomation since 2007. 14 Rattlesnake ( Crotalus and Sistrurus spp. ) envenomation commonly causes thrombocytopenia and hypofi brinogenemia. 15 -17 These venom-induced coagulopathies usually improve, but an estimated one-third to more than one-half of them recur in the days to weeks following treatment with Fab antivenom. 18, 19 Recurrent coagulopathy is almost always as severe as the presenting coagulopathy and sometimes worse. 20 In addition, new-onset late coagulopathies develop in many instances despite a full course of Fab antivenom treatment. When exactly and if coagulation abnormalities will develop and nadir are diffi cult to predict. 21, 22 Furthermore, coagulopathies sometimes persist, even with repeated doses of Fab antivenoms, and transfusions are ineffective. 9,23 Studies in Asia and Africa conclude that more often repeated doses of Fab antivenoms are not required with antigen-binding fragment antivenoms, but that F(ab ' ) 2 is more effective than Fab at restoring blood coagulability. 24, 25 Frequent monitoring and follow-up are necessary with Fab antivenoms, along with additional intervention, hospitalization and cost. 22 Serious bleeding complications and deaths have resulted from late coagulopathies after treatment of viper (e.g., Crotalus adamanteus * , C. atrox, C. ruber * , C. oreganus oreganus , C. horridus , and Bothrops alternatus * ; Viperidae) envenomation with a Fab antivenom. 23,26 -30 [ * -deaths] 
Goals of this investigation
Recurrence of coagulopathy appear, at least in part, to be caused by a pharmacokinetic mismatch between venom and antivenom, probably because a depot of venom remains at the bite site, distributing into the surrounding tissues and circulation according to the properties and kinetics of its various toxins. 9 IgG, F(ab ' ) 2 , and Fab differ in molecular mass, volume of distribution, and elimination half-life. 9 A Phase 2 clinical trial explored the relationship of venom antigenemia ( " venonemia " ) with recurrent coagulopathy, showing a clear difference between the patterns with F(ab ' ) 2 versus Fab antivenom during the 2 weeks following treatment of envenomation. 18 No recurrence was observed in patients treated with F(ab ' ) 2 in preliminary Phase 2 study, but larger studies were necessary for confi rmation or negation of this fi nding. We hypothesized that F(ab ' ) 2 antivenom would be superior to Fab in the prevention of late coagulopathy following treatment of envenomation. To test this hypothesis, we conducted a prospective, multicenter, blinded, randomized, controlled Phase 3 clinical trial comparing F(ab ' ) 2 to Fab for the treatment of patients with Crotalinae envenomation.
Methods

Study design
In this prospective, blinded, randomized, controlled clinical trial, prevention of late coagulopathy using F(ab ' ) 2 versus Fab antivenom was compared in treatment of Crotalinae envenomation at 18 clinical sites in the US. The Institutional Review Board at each site approved the study protocol. The study was registered at ClinicalTrials.gov, number NCT00636116.
Materials
The Fab antivenom was Crotalidae polyvalent immune Fab (ovine) (CroFab ® , " Fab " ), a commercial product. Immunizing venoms used to produce it are from C. adamanteus , C. atrox , C. scutulatus , and Agkistrodon piscivorus . This preparation is purifi ed via sodium sulfate precipitation and affi nity chromatography. Protein content of each vial is " up to 1 g, " according to the manufacturer. 12 The F(ab ' ) 2 antivenom was Crotalidae equine immune F(ab ' ) 2 [Anavip ® , " F(ab ' ) 2 " ], an investigational new drug. Immunizing venoms for this product are from B. asper and C. simus . This preparation is purifi ed via ammonium sulfate precipitation and fi ltration. F(ab ' ) 2 contains approximately 120 mg of protein per vial. 13 A relative potency of one vial of Fab to two vials of F(ab ' ) 2 was assigned based on a Phase 2 clinical trial and mouse ED 50 comparisons. 18, 31 Study drugs and monitoring were provided by sponsors Instituto Bioclon, SA de CV, and Rare Disease Therapeutics, Inc. " Study drug " was whichever antivenom and/or placebo combination the subject was randomized to receive.
Selection of participants
Eligible patients were males and females aged 2 -80 years presenting for emergency treatment of a Crotalinae bite and able to provide informed consent. Signs of envenomation (as judged by clinician investigators) were swelling, tenderness, redness, ecchymosis, or blebs emanating from the bite site; decreased platelets or fi brinogen; and hypotension, bleeding beyond the puncture site, refractory vomiting or diarrhea, angioedema, or neurotoxicity. Exclusion criteria included pregnancy; breast-feeding; current treatment with antivenom or treatment with antivenom within the last month; participation in a clinical trial within the previous month; allergy to horse serum, sheep serum, or papaya; no clinical indications of snakebite requiring antivenom for treatment (i.e., no local tissue injury other than tooth marks and no lab abnormalities or systemic abnormalities consistent with snake venom toxicity); and underlying medical conditions or medications that signifi cantly alter platelet count or fi brinogen. The study took place from May 2008 through September 2011, and patients were followed for 22 days after enrollment.
Interventions
Randomization was done using Statistical Analysis Software (Cary, NC). Three treatment arms [F(ab ' ) 2 with F(ab ' ) 2 maintenance therapy, F(ab ' ) 2 with placebo maintenance therapy, and Fab with Fab maintenance therapy] were established, in a 1:1:1 ratio with a block size of 6. After informed consent was granted, a study pharmacist contacted an Interactive Voice Response System (Covance, Inc, Princeton NJ) to learn the group assignment. Study drug was reconstituted and diluted to 250 mL with normal saline (NS). Placebo consisted of 250 mL of NS only. To ensure blinding of all other participants, study drug was provided to clinicians with no reference to group assignment. Study subjects, all investigators and care providers, the IND sponsor, and study monitors remained blinded until completion of the study.
Study drug was infused intravenously over 1 hour. Initial dose(s) consisted of 10 vials of F(ab ' ) 2 or 5 vials of Fab administered every 2 hours until " Initial Control " of the envenomation was achieved, meaning that (1) the leading edge of local injury was not progressing more than 1 inch per hour, and (2) platelet count, serum fi brinogen level, prothrombin time (PT), and partial thromboplastin time (PTT) were either normal or returning toward normal. After initial control, maintenance dosing of 4 vials of F(ab ' ) 2 [for the F(ab ' ) 2 /F(ab ' ) 2 group] or 250 mL of NS [for the F(ab ' ) 2 / placebo group] or 2 vials of Fab (for the Fab/Fab group) was administered every 6 hours for 3 doses. At any time during the study, patients with ongoing signs of envenomation could receive an additional 4 vials of F(ab ' ) 2 or 2 vials of Fab, in accordance with group assignment, at physician discretion, maintaining the blind.
Measurements
Patients had the following assessments and measurements recorded at baseline: history, medications, vital signs, physical examination, and a urine or blood pregnancy test; blood was drawn for complete blood count (CBC) PT/PTT, fi brinogen, venom, and antivenom levels; the subfamily, genus, and species of the snake were identifi ed if possible; the physician or study nurse drew a line on the patient ' s skin indicating the proximal leading edge of the lesion; and Snakebite Severity Score (SSS) 32 was assessed. On completion of the initial infusion, the physician or study nurse drew another line on the patient ' s skin to compare with the previous line and to facilitate subsequent assessments of ongoing local injury. Lesion assessment and repeat labs (CBC, PT/INR (International Normalized Ratio), fi brinogen, and venom/antivenom levels) were drawn 2 hours after the start of the initial infusion and 2 hours after the start of each additional infusion until initial control was achieved. Vitals were repeated 2 hours after start of each maintenance dose, and lab tests were repeated 2 hours after start of the third maintenance dose. At each follow-up visit on days 5, 8, and 15, patients had vitals taken, lab results obtained, and an assessment for any symptoms or signs suggestive of recurrent venom effect or adverse event (AE). The reason for this periodicity of follow-up was based on the documented range of recurrence chronology. During the follow-up phone call on day 22, concomitant medications and AEs were reviewed with the patient.
Outcomes
The primary effi cacy endpoint was defi ned as coagulopathy between the end of maintenance dosing and study day 8 ( ϩ / Ϫ 1 day). Coagulopathy was defi ned as platelet count less than 150,000/mm 3 , fi brinogen less than 150 mg/dL, or use of antivenom to treat a coagulation abnormality between the end of maintenance dosing and study day 5. Secondary effi cacy endpoints included platelet counts, fi brinogen levels, and venom levels.
Safety monitoring included specifi c overall assessment for acute and delayed serum reactions, clinical evidence of bleeding or coagulopathy, and other individual AEs regardless of apparent cause. AE seriousness, frequency, intensity, relationship to study drug, action taken, and outcome were recorded and clinically judged by investigators. AEs were monitored for 22 days.
Data analysis
Sample size calculations were based on predicted rates of coagulopathy during follow-up of 35 percent for Fab and 5 percent for F(ab ' ) 2 . This difference in proportions would yield a moderate effect size. Under these assumptions, a sample size of 36 patients per treatment group gave greater than 80% power to detect a difference in coagulopathy rates between treatments. The total number (108) was later amended to 120, to allow a reasonable power for analyses even if up to 10% of patients withdrew from the study or were eliminated because of protocol deviations. The trial ended when the enrollment goal was reached. The primary effi cacy analysis was based on the intent-to-treat (ITT) population.
The null hypothesis assumed no difference in coagulopathy incidence between treatments, the alternative hypothesis is that F(ab ' ) 2 is superior to Fab. Any fi brinogen level less than 60 was analyzed as 60 mg/dL, favoring the null hypothesis. For the primary effi cacy endpoint, separate pairwise comparisons between each F(ab ' ) 2 group versus the Fab group were performed using Fisher ' s exact test. The Bonferroni -Holm method was used to preserve a family-wise type I error rate of 0.05. 33 For all other analyses, a similar method was employed. Categorical outcomes were analyzed using Fisher ' s exact test; continuous outcomes were analyzed using analysis of variance (ANOVA). Statistical analyses were performed using IBM SPSS Statistics for Macintosh, 21.0, Armonk, NY, and power calculation was performed using PASS 2005, NCSS, LLC, Kaysville, UT.
Results
Characteristics of study subjects A total of 123 patients were randomized, 41 in each group, of which 121 received antivenom and 114 completed the study (Fig. 1 ). There were no differences in gender, eth- Fig. 1 . CONSORT fl ow diagram (colour version of this fi gure can be found in the online version at www.informahealthcare.com/ctx). nicity, baseline mean platelet count or fi brinogen level, SSS, or time to antivenom administration among groups (Table 1 ). The F(ab ' ) 2 /F(ab ' ) 2 group included more children and was younger on average than the Fab/Fab group. Eighteen study sites in 8 states participated in the study: AZ, CA, FL, KS, LA, NC, NM, and TX. Protocol deviations related to study drug type or dose occurred in 6 cases. The identifi ed snake species included C. oreganus helleri , C. scutulatus , C. mitchellii , C. atrox , C. cerastes , C. ruber , C. viridis , C. molossus , C. horridus , S. miliarius barbouri , A. contortrix, and a single A. piscivorus . Copperhead bites affected 6 in the F(ab ' ) 2 /F(ab ' ) 2 group, 7 in F(ab ' ) 2 /placebo group, and 8 in the Fab/Fab group. One cottonmouth bite was identifi ed in the Fab/Fab group. The rest were rattlesnake or unidentifi ed bites ( n ϭ 102).
Effi cacy
Coagulopathy was less frequent in the F(ab ' ) 2 /F(ab ' ) 2 and the F(ab ' ) 2 /placebo groups compared with that in the Fab/ Fab group, and there was an absolute risk reduction in both F(ab ' ) 2 groups compared with that in Fab group (Table 2 ). The lowest platelet counts were lower in the Fab group compared with those in both the F(ab ' ) 2 groups. The lowest fi brinogen levels were lower in the Fab group compared with those in the F(ab ' ) 2 /placebo group. The only patients with fi brinogen levels less than 60 mg/dL ( n ϭ 2) and platelet counts less than 50,000/mm 3 ( n ϭ 2) after initial control were in the Fab group. Post-hoc review of venom and antivenom levels by Instituto Bioclon suggested that analyte degradation during transport and prolonged storage at -20 may have reduced signal intensity to such an extent that comparison of results across groups was invalidated. For this reason, these results were excluded from this analysis.
None of the children Ͻ 10 years old ( n ϭ 18; 15.8%) experienced late coagulopathy. Six extra doses were given to F(ab ' ) 2 /F(ab ' ) 2 recipients, eleven to F(ab ' ) 2 /placebo recipients, and eighteen to Fab/Fab recipients. Of 6 patients treated with F(ab ' ) 2 who experienced late coagulopathy, all manifested at a single site in inland southern California; the species, identifi ed by the fi rst author, were C. oreganus helleri ( n ϭ 2), C. mitchellii , C. ruber , C. atrox , and one unknown Crotalus sp. Late coagulopathy occurred in Fab patients at 7 sites: in California ( n ϭ 8), Arizona ( n ϭ 5), New Mexico ( n ϭ 2), Florida ( n ϭ 1), and North Carolina ( n ϭ 1). Removal of protocol deviation cases from the ITT analysis did not affect signifi cance of results.
Adverse events and safety
Overall, fewer AEs were reported in the F(ab ' ) 2 /placebo group than in the F(ab ' ) 2 /F(ab ' ) 2 or Fab/Fab (Table 3 ). The majority of events reported in all three of the study groups were assessed as mild. Nine patients experienced Serious AEs (SAEs), all assessed as unrelated to study drug. One patient in the F(ab ' ) 2 /F(ab ' ) 2 group died on Day 7 from injuries related to a traffi c collision. One SAE in the Fab/Fab group was related to multicomponent coagulopathy recurrence and persistence, with major extension of ecchymosis on day 2, bleeding from an intrajugular intravenous site on day 6, and a 10-g drop in hemoglobin during an 11-day hospital course.
One patient in each arm of the study experienced an acute serum reaction; however, all three tolerated subsequent doses after resolution of the AEs. One patient in each group experienced a pattern of symptoms suggestive of serum sickness during follow-up. No immune reaction was severe.
Mean antivenom dose in terms of vials was similar for the F(ab ' ) 2 /placebo (16.1 Ϯ 7.89, range: 5 -38) and Fab/Fab (14.2 Ϯ 5.66, range: 7 -38) groups, but greater in the F(ab ' ) 2 / F(ab ' ) 2 (27.2 Ϯ 7.25, range: 22 -46) group. Maximum total protein exposure was 3.5 -6 times greater in the Fab group than that in either of the F(ab ' ) 2 groups.
Discussion
This study supports the hypothesis that management of US Crotalinae envenomation using an F(ab ' ) 2 antivenom reduces subacute coagulopathies following treatment in comparison with that using Fab antivenom. An absolute risk reduction of 19.5 -24.5 percent would suggest that 4 -5 patients would need to be treated with F(ab ' ) 2 to result in fewer cases of late coagulopathy. Serious bleeding complications after treatment with Fab occurred in our study, consistent with past reports. 23,26 -30 This implies that use of F(ab ' ) 2 antivenom could reduce medically signifi cant late bleeding after snakebite, and that the need for repeated blood testing after treatment could be reduced. In addition, our study suggests that maintenance dosing is not required with F(ab ' ) 2 to prevent late coagulopathy. Table 3 . Adverse events (Safety population). The specifi c F(ab ' ) 2 and Fab antivenoms compared in this study differ in many ways, most obviously not only in the structure and mass of the molecule but also in the venom immunogens used, affi nity purifi cation, protein content, and pharmacokinetics. Each of these variables could have infl uenced effi cacy, and so each is considered. First, Fab is produced using venoms from snake species indigenous to the US, whereas venoms for manufacturing F(ab ' ) 2 come from Latin American species. Venom composition and antigenicity can vary considerably with species 34 and geographic 35 origin of a snake; it is commonly assumed that venom immunogens derived from local species produce more regionally effective antivenom. 24 Our study showed the opposite, suggesting that this was less important than other factors. Second, Fab is affi nity purifi ed while F(ab ' ) 2 is not. Effective affi nity purifi cation should favor the per-mg potency and effi cacy of Fab, again in contradistinction to our results, which favored the lower-protein, non-affi nitypurifi ed F(ab ' ) 2 antivenom. Finally, Phase 2 data showed that clearance of Fab is associated with recurring venom antigenemia and an accompanying drop in platelet count and fi brinogen levels, in contrast with F(ab ' ) 2 , which cleared more slowly and was not associated with recurrent venom effects. 18 This difference is consistent with our Phase 3 fi ndings. Therefore, we conclude that differences in incidence of coagulopathy are principally related to antivenom kinetics. This is consistent with fi ndings in a comparative study of F(ab ' ) 2 and Fab antivenoms for Echis ocellatus envenomations in Nigeria 25 and in a comparison of F(ab ' ) 2 to Fab for restoration of blood coagulability after Daboia russellii in Sri Lanka. 24 We found no tradeoffs in safety related to immune reactions or miscellaneous AEs. The plasma source for Fab is ovine, whereas for F(ab ' ) 2 it is equine. It has been postulated that immunizing sheep rather than horses could reduce risk associated with exposure to equine-produced allergenic components, 36 but immune reactions in all groups were low in this study, without discernible differences between the two antivenoms. Safety as it relates to coagulopathy, however, was better with F(ab ' ) 2, consistent with results from Phase 2. 18
Limitations
Limitations of the study arose from the inclusion of a disproportionate number of children in the F(ab ' ) 2 /F(ab ' ) 2 group compared with that in the Fab/Fab group. None of the 17 children treated with F(ab ' ) 2 experienced late coagulopathy; however, late coagulopathies, some with medically signifi cant late bleeding, have been reported in children less than 10 years old, suggesting that the confounding effect of this group should be minimal. 26, 37 This study was not powered to demonstrate the interaction of different snake venoms or site-specifi c populations with the primary endpoint, but the difference in geographic distribution of coagulopathic cases suggests that future studies should consider the effects of heterologous antivenom(s) on many US Crotalinae species .
Conclusions
For envenomation by North American Crotalinae snakes capable of causing unexpected bleeding, this study found that management with longer-half-life F(ab ' ) 2 antivenom reduces the risk of post-treatment recurrence and late-onset coagulopathies following treatment when compared with management with Fab. Until such time as F(ab ' ) 2 is commercially utilized in the US, patients with Crotalinae envenomation will be at continued risk for medically signifi cant late bleeding complications (including death) in the days and weeks following treatment with Fab.
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